Vermillion Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Vermillion Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$514	Hold	140	–	–	﹤0.01%	1492
2026 Q1	$430	Hold	140	–	–	﹤0.01%	1070
2025 Q4	$573	Hold	140	–	–	﹤0.01%	569
2025 Q3	$683	Hold	140	–	–	﹤0.01%	1462
2025 Q2	$708	Hold	140	–	–	﹤0.01%	489
2025 Q1	$741	Sell	140 -13	-8%	-$95	﹤0.01%	1245
2024 Q4	$1.03K	Buy	+153	New	+$1.03K	﹤0.01%	486

Other funds holding RXRX

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

AWM

Accel Wealth Management Waverly, Iowa $444M AUM 31.14% 1-Year Est. Return

NWMG

National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return

WPC

Wedmont Private Capital West Chester, Pennsylvania $3.65B AUM 26.64% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

ICP

Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return

Vermillion Wealth Management's RXRX Position: Q2 2026 in Review

Vermillion Wealth Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 140 shares worth $514. The position accounts for ﹤0.01% of the portfolio, ranked #1492.

Vermillion Wealth Management first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.03K in Q4 2024. 28 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Vermillion Wealth Management held 140 shares of Recursion Pharmaceuticals worth $514 as of Q2 2026.
Vermillion Wealth Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Vermillion Wealth Management's portfolio in Q2 2026, its #1492 holding.
Vermillion Wealth Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Vermillion Wealth Management's Recursion Pharmaceuticals position peaked at $1.03K in Q4 2024.
28 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.